Daniel Allen - 28 Dec 2022 Form 4 Insider Report for PharmaCyte Biotech, Inc. (PMCB)

Reporting relationship: Director
Issuer ticker: PMCB
Reported as of: 28 Dec 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Dec 2022, 15:05:37 UTC
Prior SEC filing: 24 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ Daniel Allen

Key filing fact

Daniel Allen filed Form 4 for PharmaCyte Biotech, Inc. (PMCB) on 30 Dec 2022.

Key facts

This page summarizes Daniel Allen's Form 4 filing for PharmaCyte Biotech, Inc. (PMCB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Dec 2022, 15:05.

Change

Previous filing in this sequence was filed on 24 Aug 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PMCB transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +125,000
Change %
Price: $0.000000
Shares after: 125,000
Date: 28 Dec 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125,000
Exercise price: $2.97
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Daniel Allen is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

The option grant was approved by the Issuer's board of directors on November 14, 2022, subject to stockholder approval of the PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan (the "2022 Plan"), under which the option was granted. The Issuer's stockholders approved the 2022 Plan on December 28, 2022.